SION earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -23.33. Updated 2026-07-23.
Sionna Therapeutics (SION) Research Hub
Sionna Therapeutics (SION) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 7.85 USD (+4.95%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -23.33, market cap 2.04B. This hub links to the full technical, earnings and options research available for SION.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.85 USD (+4.95%) |
| 52-week range | 4.49 USD – 54.97 USD |
| Trend regime | Range |
| 14-day RSI | 9 (Oversold) |
| Trailing P/E | -23.33 |
| Market cap | 2.04B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for SION
Covered Call on SION: how it works, illustrative setup around the real 7.85 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SION: how it works, illustrative setup around the real 7.85 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SION: how it works, illustrative setup around the real 7.85 USD price, max profit/loss, breakeven and when to use it. Educational.
SION technical analysis: range, last 7.85 USD, RSI 9, 52w range 4.49 USD–54.97 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SION in?
Sionna Therapeutics (SION) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SION in an uptrend or downtrend?
As of 2026-09-11, SION is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SION's trailing P/E ratio?
SION's trailing P/E is -23.33, with a market cap of 2.04B. See the earnings research page for full valuation detail.
When does SION next report earnings?
SION is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.64 USD.